植入式心律調節器市場- 按產品（單腔起搏器、雙腔起搏器、雙心室/CRT 起搏器）、按應用（心動過緩、心律不整）、最終用途（醫院和診所、心臟護理中心、ASC）和預測，2024 年 - 2032

預計2024 年至2032 年間，植入式心律調節器市場規模的複合年成長率將達到4.6%，原因是心血管疾病（尤其是心律不整、心臟阻塞和心房顫動）盛行率不斷上升，需要使用起搏器來調節心律。據報道，心房顫動影響全球約 4,000 萬人。醫療技術的不斷進步促進了更複雜、更可靠的心律調節器設備的開發，包括相容於 MRI 的起搏器和無鉛起搏器，以提高患者的安全性和舒適度。

增強的診斷能力和更容易獲得先進的心臟護理也使得能夠更早發現和治療需要起搏器干預的心臟疾病。患者和醫療保健提供者對心臟健康的認知不斷提高，以及早期干預的好處，有助於提高植入式起搏器的採用率。各國政府的措施和有利的報銷政策也有助於使患者更容易獲得這些救生設備。

植入式心律調節器產業分為產品、應用、最終用途和地區。

從產品來看，由於其成本效益和簡單性，單腔起搏器細分市場的市場規模將在2024 年至2032 年期間產生可觀的收入，使其成為對患者和醫療保健提供者都有吸引力的選擇。單腔心律調節器通常更容易植入，需要更短的手術時間，同時減少併發症和住院時間的風險。它們對患有特定類型心律不整的患者特別有益，例如伴有心搏過緩的房顫，主要需要在心室的一個心室起搏。

由於心房顫動、心搏過緩和心臟傳導阻滯等各種心律不整的高盛行率和不斷增加的診斷，心律不整應用領域的植入式起搏器市場預計將在2024 年至2032 年出現強勁成長。這些情況會擾亂心臟的正常節律，導致疲勞、頭暈和昏厥等症狀，嚴重影響患者的生活品質。

亞太地區植入式心律調節器產業規模預計在 2024 年至 2032 年期間出現可觀的成長。這是由於日本、中國和韓國等國家的人口迅速老化，導致需要起搏器干預的心血管疾病發生率更高。城市化進程的加速和生活方式的改變也將導致心臟相關疾病的增加，從而推動區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 心血管疾病盛行率增加
    • 技術進步
    • 擴大轉向微創手術
    • 有利的報銷方案
  • 產業陷阱與挑戰
    • 植入式心律調節器成本高
    • 風險和併發症
• 成長潛力分析
• 監管環境
• 技術景觀
• 未來市場趨勢
• 報銷場景
• 波特的分析
• PESTEL分析
• 定價分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 單腔起搏器
  • 單腔心房
  • 單腔心室
• 雙腔起搏器
• 雙心室/CRT起搏器

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 心搏過緩
• 心律不整
• 其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 心臟護理中心
• 門診手術中心
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories, Inc.
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Lepu Medical Technology
• Medico S.R.L.
• Medtronic plc
• MicroPort Scientific Corporation
• Shree Pacetronix Ltd.
• Vitatron

Implantable pacemakers market size is predicted to register 4.6% CAGR between 2024 and 2032, driven by increasing prevalence of cardiovascular diseases, particularly arrhythmia's, heart blockages, and atrial fibrillation, which necessitate the use of pacemakers to regulate heart rhythms. As per reports, atrial fibrillation affects around 40 million people worldwide. Rising advancements in medical technologies have led to the development of more sophisticated and reliable pacemaker devices, including MRI-compatible pacemakers and lead less pacemakers to offer enhanced patient safety and comfort.

Enhanced diagnostic capabilities and greater accessibility to advanced cardiac care are also enabling earlier detection and treatment of heart conditions that require pacemaker intervention. Rising awareness about heart health and the benefits of early intervention among both patients and healthcare providers are contributing to higher adoption rates of implantable pacemakers. Government initiatives and favorable reimbursement policies in various countries are also helping in making these life-saving devices more accessible to patients.

The implantable pacemakers industry is segmented into product, application, end-use and region.

Based on product, the market size from the single chamber pacemakers segment will generate substantial revenue from 2024-2032 due to its cost-effectiveness and simplicity, making it an attractive option for both patients and healthcare providers. Single chamber pacemakers are typically easier to implant and require shorter surgical times while reducing the risk of complications and hospital stays. They are particularly beneficial for patients with specific types of arrhythmia's, such as atrial fibrillation with bradycardia, where pacing is needed primarily in one chambers of the heart.

Implantable pacemakers market from the arrhythmia's application segment is anticipated to witness strong growth over 2024-2032 owing to the high prevalence and increasing diagnosis of various cardiac rhythm disorders, such as atrial fibrillation, bradycardia, and heart block. These conditions disrupt the normal rhythm of the heart, leading to symptoms like fatigue, dizziness, and fainting, for significantly impacting the quality of life of the patients.

Asia Pacific implantable pacemakers industry size is slated to witness decent growth rate during 2024-2032. This is attributed to the rapidly aging population in countries like Japan, China, and South Korea, which is leading to the higher incidence of cardiovascular diseases that require pacemaker intervention. Increasing urbanization and lifestyle changes will also contribute to the rise in heart-related conditions, driving the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Rising shift towards minimally invasive procedures
    • 3.2.1.4 Favorable reimbursement scenario
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of implantable pacemakers
    • 3.2.2.2 Risks and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Reimbursement scenario
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Pricing analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Single-chamber pacemakers
  • 5.2.1 Single-chamber atrial
  • 5.2.2 Single-chamber ventricular
• 5.3 Dual-chamber pacemakers
• 5.4 Bi ventricular/CRT pacemakers

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Bradycardia
• 6.3 Arrhythmia
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Cardiac care centers
• 7.4 Ambulatory surgical centers
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories, Inc.
• 9.2 BIOTRONIK SE & Co. KG
• 9.3 Boston Scientific Corporation
• 9.4 Lepu Medical Technology
• 9.5 Medico S.R.L.
• 9.6 Medtronic plc
• 9.7 MicroPort Scientific Corporation
• 9.8 Shree Pacetronix Ltd.
• 9.9 Vitatron